A recent study published in The Lancet Digital Health demonstrates that artificial intelligence can extract molecular and prognostic data from standard hematoxylin and eosin pathology slides, offering a cost-effective alternative to DNA methylation profiling for classifying meningiomas and predicting recurrence risk. Led by Dr. Gelareh Zadeh at Mayo Clinic in Rochester, the research trained deep learning models on tissue samples, pathology images, and clinical data from 672 patients. The AI successfully identified meningioma subtypes and forecasted tumor behavior, capturing decades of genomic knowledge into accessible algorithms. Meningiomas represent the most common primary adult brain tumor, with clinical outcomes ranging from indolent growth to aggressive recurrence. Determining recurrence likelihood is essential for postoperative management, including radiation therapy planning and surveillance frequency. While DNA methylation testing provides precise prognostic insights, its high cost, technical complexity, and limited hospital availability restrict widespread adoption. The AI platform addresses this gap by leveraging routinely generated pathology slides, which are already standard in clinical workflows. Crucially, the model predictive accuracy remained robust after controlling for established clinical variables, including tumor grade, surgical resection extent, and patient age. The system also detected intratumoral heterogeneity patterns, potentially explaining variable treatment responses. Researchers emphasize that prospective validation is required before clinical deployment, but the findings establish a scalable framework for demystifying tumor biology without advanced genomic sequencing. Dr. Zadeh noted the initiative aims to integrate these algorithms into global health infrastructure, expanding access to precision oncology. If validated in broader trials, the technology could be adapted to other malignancies, fundamentally reducing reliance on expensive molecular diagnostics while standardizing risk stratification across diverse healthcare settings.